nodes	percent_of_prediction	percent_of_DWPC	metapath
Silodosin—UGT2B7—Epirubicin—thyroid cancer	0.543	0.651	CbGbCtD
Silodosin—ABCB1—Sorafenib—thyroid cancer	0.0816	0.0978	CbGbCtD
Silodosin—CYP3A4—Vandetanib—thyroid cancer	0.0811	0.0972	CbGbCtD
Silodosin—ABCB1—Doxorubicin—thyroid cancer	0.0495	0.0593	CbGbCtD
Silodosin—CYP3A4—Sorafenib—thyroid cancer	0.0489	0.0586	CbGbCtD
Silodosin—CYP3A4—Doxorubicin—thyroid cancer	0.0297	0.0356	CbGbCtD
Silodosin—Rhinorrhoea—Sorafenib—thyroid cancer	0.00489	0.0337	CcSEcCtD
Silodosin—Nasopharyngitis—Vandetanib—thyroid cancer	0.00381	0.0263	CcSEcCtD
Silodosin—Hepatic function abnormal—Sorafenib—thyroid cancer	0.00329	0.0227	CcSEcCtD
Silodosin—Hepatobiliary disease—Vandetanib—thyroid cancer	0.00311	0.0214	CcSEcCtD
Silodosin—Sinusitis—Vandetanib—thyroid cancer	0.00308	0.0212	CcSEcCtD
Silodosin—Cardiac disorder—Vandetanib—thyroid cancer	0.00274	0.0188	CcSEcCtD
Silodosin—ABCB4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.0027	0.131	CbGpPWpGaD
Silodosin—Angiopathy—Vandetanib—thyroid cancer	0.00268	0.0184	CcSEcCtD
Silodosin—Mediastinal disorder—Vandetanib—thyroid cancer	0.00266	0.0183	CcSEcCtD
Silodosin—Breast disorder—Sorafenib—thyroid cancer	0.0026	0.0179	CcSEcCtD
Silodosin—Mental disorder—Vandetanib—thyroid cancer	0.00258	0.0178	CcSEcCtD
Silodosin—Nasopharyngitis—Sorafenib—thyroid cancer	0.00257	0.0177	CcSEcCtD
Silodosin—Erectile dysfunction—Sorafenib—thyroid cancer	0.00229	0.0158	CcSEcCtD
Silodosin—Loss of consciousness—Vandetanib—thyroid cancer	0.00226	0.0155	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00217	0.0149	CcSEcCtD
Silodosin—Jaundice—Sorafenib—thyroid cancer	0.00216	0.0149	CcSEcCtD
Silodosin—Dry mouth—Vandetanib—thyroid cancer	0.00214	0.0147	CcSEcCtD
Silodosin—Hepatobiliary disease—Sorafenib—thyroid cancer	0.0021	0.0144	CcSEcCtD
Silodosin—Nervous system disorder—Vandetanib—thyroid cancer	0.00206	0.0141	CcSEcCtD
Silodosin—Skin disorder—Vandetanib—thyroid cancer	0.00204	0.014	CcSEcCtD
Silodosin—Insomnia—Vandetanib—thyroid cancer	0.0019	0.013	CcSEcCtD
Silodosin—Cardiac disorder—Sorafenib—thyroid cancer	0.00185	0.0127	CcSEcCtD
Silodosin—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00181	0.0125	CcSEcCtD
Silodosin—Angiopathy—Sorafenib—thyroid cancer	0.00181	0.0124	CcSEcCtD
Silodosin—Immune system disorder—Sorafenib—thyroid cancer	0.0018	0.0124	CcSEcCtD
Silodosin—Mediastinal disorder—Sorafenib—thyroid cancer	0.00179	0.0123	CcSEcCtD
Silodosin—Mental disorder—Sorafenib—thyroid cancer	0.00174	0.012	CcSEcCtD
Silodosin—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00171	0.0118	CcSEcCtD
Silodosin—Abdominal pain—Vandetanib—thyroid cancer	0.00166	0.0114	CcSEcCtD
Silodosin—Syncope—Sorafenib—thyroid cancer	0.00155	0.0107	CcSEcCtD
Silodosin—Loss of consciousness—Sorafenib—thyroid cancer	0.00152	0.0105	CcSEcCtD
Silodosin—Asthenia—Vandetanib—thyroid cancer	0.0015	0.0104	CcSEcCtD
Silodosin—Pruritus—Vandetanib—thyroid cancer	0.00148	0.0102	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00146	0.0101	CcSEcCtD
Silodosin—Dry mouth—Sorafenib—thyroid cancer	0.00144	0.00993	CcSEcCtD
Silodosin—Diarrhoea—Vandetanib—thyroid cancer	0.00143	0.00987	CcSEcCtD
Silodosin—Shock—Sorafenib—thyroid cancer	0.00139	0.00958	CcSEcCtD
Silodosin—Nervous system disorder—Sorafenib—thyroid cancer	0.00139	0.00954	CcSEcCtD
Silodosin—Dizziness—Vandetanib—thyroid cancer	0.00139	0.00954	CcSEcCtD
Silodosin—Skin disorder—Sorafenib—thyroid cancer	0.00137	0.00945	CcSEcCtD
Silodosin—Rash—Vandetanib—thyroid cancer	0.00132	0.0091	CcSEcCtD
Silodosin—Dermatitis—Vandetanib—thyroid cancer	0.00132	0.00909	CcSEcCtD
Silodosin—Headache—Vandetanib—thyroid cancer	0.00131	0.00904	CcSEcCtD
Silodosin—Nausea—Vandetanib—thyroid cancer	0.00124	0.00857	CcSEcCtD
Silodosin—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00122	0.0084	CcSEcCtD
Silodosin—Hepatic function abnormal—Epirubicin—thyroid cancer	0.00122	0.00837	CcSEcCtD
Silodosin—Vascular purpura—Epirubicin—thyroid cancer	0.00119	0.00818	CcSEcCtD
Silodosin—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00116	0.00796	CcSEcCtD
Silodosin—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.00113	0.00775	CcSEcCtD
Silodosin—Urticaria—Sorafenib—thyroid cancer	0.00112	0.00773	CcSEcCtD
Silodosin—Abdominal pain—Sorafenib—thyroid cancer	0.00112	0.00769	CcSEcCtD
Silodosin—Purpura—Epirubicin—thyroid cancer	0.0011	0.00759	CcSEcCtD
Silodosin—Vascular purpura—Doxorubicin—thyroid cancer	0.0011	0.00757	CcSEcCtD
Silodosin—ABCB4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.00107	0.0519	CbGpPWpGaD
Silodosin—Purpura—Doxorubicin—thyroid cancer	0.00102	0.00703	CcSEcCtD
Silodosin—Asthenia—Sorafenib—thyroid cancer	0.00101	0.00698	CcSEcCtD
Silodosin—Pruritus—Sorafenib—thyroid cancer	0.001	0.00689	CcSEcCtD
Silodosin—Liver function test abnormal—Epirubicin—thyroid cancer	0.000981	0.00676	CcSEcCtD
Silodosin—Orthostatic hypotension—Epirubicin—thyroid cancer	0.000971	0.00668	CcSEcCtD
Silodosin—Diarrhoea—Sorafenib—thyroid cancer	0.000967	0.00666	CcSEcCtD
Silodosin—Breast disorder—Epirubicin—thyroid cancer	0.000961	0.00661	CcSEcCtD
Silodosin—Nasopharyngitis—Epirubicin—thyroid cancer	0.00095	0.00654	CcSEcCtD
Silodosin—Dizziness—Sorafenib—thyroid cancer	0.000935	0.00644	CcSEcCtD
Silodosin—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000908	0.00625	CcSEcCtD
Silodosin—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000898	0.00618	CcSEcCtD
Silodosin—Rash—Sorafenib—thyroid cancer	0.000891	0.00614	CcSEcCtD
Silodosin—Dermatitis—Sorafenib—thyroid cancer	0.00089	0.00613	CcSEcCtD
Silodosin—Breast disorder—Doxorubicin—thyroid cancer	0.000889	0.00612	CcSEcCtD
Silodosin—Headache—Sorafenib—thyroid cancer	0.000886	0.0061	CcSEcCtD
Silodosin—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000879	0.00606	CcSEcCtD
Silodosin—Nausea—Sorafenib—thyroid cancer	0.00084	0.00578	CcSEcCtD
Silodosin—Jaundice—Epirubicin—thyroid cancer	0.000798	0.0055	CcSEcCtD
Silodosin—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000775	0.00533	CcSEcCtD
Silodosin—Sinusitis—Epirubicin—thyroid cancer	0.000768	0.00529	CcSEcCtD
Silodosin—Jaundice—Doxorubicin—thyroid cancer	0.000739	0.00509	CcSEcCtD
Silodosin—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000717	0.00494	CcSEcCtD
Silodosin—Sinusitis—Doxorubicin—thyroid cancer	0.000711	0.0049	CcSEcCtD
Silodosin—Cardiac disorder—Epirubicin—thyroid cancer	0.000682	0.0047	CcSEcCtD
Silodosin—Angiopathy—Epirubicin—thyroid cancer	0.000667	0.00459	CcSEcCtD
Silodosin—Immune system disorder—Epirubicin—thyroid cancer	0.000664	0.00457	CcSEcCtD
Silodosin—Mediastinal disorder—Epirubicin—thyroid cancer	0.000663	0.00456	CcSEcCtD
Silodosin—ABCB4—PPARA activates gene expression—RXRA—thyroid cancer	0.000662	0.0321	CbGpPWpGaD
Silodosin—ABCB4—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.000648	0.0314	CbGpPWpGaD
Silodosin—Mental disorder—Epirubicin—thyroid cancer	0.000644	0.00444	CcSEcCtD
Silodosin—Cardiac disorder—Doxorubicin—thyroid cancer	0.000631	0.00435	CcSEcCtD
Silodosin—Angiopathy—Doxorubicin—thyroid cancer	0.000617	0.00425	CcSEcCtD
Silodosin—Immune system disorder—Doxorubicin—thyroid cancer	0.000615	0.00423	CcSEcCtD
Silodosin—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000613	0.00422	CcSEcCtD
Silodosin—Mental disorder—Doxorubicin—thyroid cancer	0.000596	0.0041	CcSEcCtD
Silodosin—Syncope—Epirubicin—thyroid cancer	0.000574	0.00395	CcSEcCtD
Silodosin—Palpitations—Epirubicin—thyroid cancer	0.000566	0.00389	CcSEcCtD
Silodosin—Loss of consciousness—Epirubicin—thyroid cancer	0.000563	0.00387	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000541	0.00373	CcSEcCtD
Silodosin—UGT2B7—Metapathway biotransformation—CHST14—thyroid cancer	0.000541	0.0263	CbGpPWpGaD
Silodosin—Dry mouth—Epirubicin—thyroid cancer	0.000533	0.00367	CcSEcCtD
Silodosin—Syncope—Doxorubicin—thyroid cancer	0.000531	0.00366	CcSEcCtD
Silodosin—Palpitations—Doxorubicin—thyroid cancer	0.000523	0.0036	CcSEcCtD
Silodosin—Loss of consciousness—Doxorubicin—thyroid cancer	0.000521	0.00358	CcSEcCtD
Silodosin—Shock—Epirubicin—thyroid cancer	0.000514	0.00354	CcSEcCtD
Silodosin—Nervous system disorder—Epirubicin—thyroid cancer	0.000512	0.00353	CcSEcCtD
Silodosin—Tachycardia—Epirubicin—thyroid cancer	0.00051	0.00351	CcSEcCtD
Silodosin—Skin disorder—Epirubicin—thyroid cancer	0.000507	0.00349	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000501	0.00345	CcSEcCtD
Silodosin—Dry mouth—Doxorubicin—thyroid cancer	0.000493	0.0034	CcSEcCtD
Silodosin—ABCB4—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000492	0.0239	CbGpPWpGaD
Silodosin—Hypotension—Epirubicin—thyroid cancer	0.000488	0.00336	CcSEcCtD
Silodosin—Shock—Doxorubicin—thyroid cancer	0.000476	0.00327	CcSEcCtD
Silodosin—Nervous system disorder—Doxorubicin—thyroid cancer	0.000474	0.00326	CcSEcCtD
Silodosin—Insomnia—Epirubicin—thyroid cancer	0.000473	0.00325	CcSEcCtD
Silodosin—Tachycardia—Doxorubicin—thyroid cancer	0.000472	0.00325	CcSEcCtD
Silodosin—Skin disorder—Doxorubicin—thyroid cancer	0.00047	0.00323	CcSEcCtD
Silodosin—Hypotension—Doxorubicin—thyroid cancer	0.000452	0.00311	CcSEcCtD
Silodosin—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000451	0.00311	CcSEcCtD
Silodosin—ABCB4—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.000446	0.0217	CbGpPWpGaD
Silodosin—Insomnia—Doxorubicin—thyroid cancer	0.000437	0.00301	CcSEcCtD
Silodosin—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000427	0.00294	CcSEcCtD
Silodosin—ABCB4—PPARA activates gene expression—PPARG—thyroid cancer	0.000418	0.0203	CbGpPWpGaD
Silodosin—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000417	0.00287	CcSEcCtD
Silodosin—Urticaria—Epirubicin—thyroid cancer	0.000415	0.00286	CcSEcCtD
Silodosin—ADRA1A—Endothelin Pathways—CALCA—thyroid cancer	0.000413	0.0201	CbGpPWpGaD
Silodosin—Abdominal pain—Epirubicin—thyroid cancer	0.000413	0.00284	CcSEcCtD
Silodosin—ABCB4—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.000409	0.0199	CbGpPWpGaD
Silodosin—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000395	0.00272	CcSEcCtD
Silodosin—Urticaria—Doxorubicin—thyroid cancer	0.000384	0.00264	CcSEcCtD
Silodosin—Abdominal pain—Doxorubicin—thyroid cancer	0.000382	0.00263	CcSEcCtD
Silodosin—Asthenia—Epirubicin—thyroid cancer	0.000375	0.00258	CcSEcCtD
Silodosin—Pruritus—Epirubicin—thyroid cancer	0.00037	0.00254	CcSEcCtD
Silodosin—Diarrhoea—Epirubicin—thyroid cancer	0.000357	0.00246	CcSEcCtD
Silodosin—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000357	0.0173	CbGpPWpGaD
Silodosin—Asthenia—Doxorubicin—thyroid cancer	0.000347	0.00239	CcSEcCtD
Silodosin—Dizziness—Epirubicin—thyroid cancer	0.000345	0.00238	CcSEcCtD
Silodosin—Pruritus—Doxorubicin—thyroid cancer	0.000342	0.00235	CcSEcCtD
Silodosin—ABCB4—Metabolism—MINPP1—thyroid cancer	0.00034	0.0165	CbGpPWpGaD
Silodosin—Diarrhoea—Doxorubicin—thyroid cancer	0.000331	0.00228	CcSEcCtD
Silodosin—Rash—Epirubicin—thyroid cancer	0.000329	0.00227	CcSEcCtD
Silodosin—Dermatitis—Epirubicin—thyroid cancer	0.000329	0.00227	CcSEcCtD
Silodosin—Headache—Epirubicin—thyroid cancer	0.000327	0.00225	CcSEcCtD
Silodosin—Dizziness—Doxorubicin—thyroid cancer	0.00032	0.0022	CcSEcCtD
Silodosin—Nausea—Epirubicin—thyroid cancer	0.00031	0.00214	CcSEcCtD
Silodosin—Rash—Doxorubicin—thyroid cancer	0.000305	0.0021	CcSEcCtD
Silodosin—Dermatitis—Doxorubicin—thyroid cancer	0.000305	0.0021	CcSEcCtD
Silodosin—Headache—Doxorubicin—thyroid cancer	0.000303	0.00208	CcSEcCtD
Silodosin—ABCB4—Metabolism—NDUFA13—thyroid cancer	0.000289	0.014	CbGpPWpGaD
Silodosin—Nausea—Doxorubicin—thyroid cancer	0.000287	0.00198	CcSEcCtD
Silodosin—ABCB4—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.000282	0.0137	CbGpPWpGaD
Silodosin—ABCB4—Metabolism—CHST14—thyroid cancer	0.000272	0.0132	CbGpPWpGaD
Silodosin—ABCB1—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000229	0.0111	CbGpPWpGaD
Silodosin—ADRA1D—Calcium Regulation in the Cardiac Cell—PRKAR1A—thyroid cancer	0.000221	0.0107	CbGpPWpGaD
Silodosin—ABCB4—Metabolism—HPGD—thyroid cancer	0.000219	0.0106	CbGpPWpGaD
Silodosin—UGT2B7—NRF2 pathway—SLC5A5—thyroid cancer	0.000217	0.0105	CbGpPWpGaD
Silodosin—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000214	0.0104	CbGpPWpGaD
Silodosin—ABCB1—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.000204	0.00989	CbGpPWpGaD
Silodosin—ADRA1D—GPCR ligand binding—CALCB—thyroid cancer	0.000204	0.00989	CbGpPWpGaD
Silodosin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—thyroid cancer	0.000203	0.00985	CbGpPWpGaD
Silodosin—ADRA1B—Calcium Regulation in the Cardiac Cell—PRKAR1A—thyroid cancer	0.000183	0.00889	CbGpPWpGaD
Silodosin—UGT2B7—NRF2 pathway—RXRA—thyroid cancer	0.000182	0.00884	CbGpPWpGaD
Silodosin—ABCB4—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000178	0.00863	CbGpPWpGaD
Silodosin—ADRA1B—GPCR ligand binding—CALCB—thyroid cancer	0.000169	0.00821	CbGpPWpGaD
Silodosin—ADRA1A—Calcium Regulation in the Cardiac Cell—PRKAR1A—thyroid cancer	0.000163	0.0079	CbGpPWpGaD
Silodosin—ABCB1—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.00016	0.00776	CbGpPWpGaD
Silodosin—UGT2B7—Biological oxidations—RXRA—thyroid cancer	0.00016	0.00776	CbGpPWpGaD
Silodosin—UGT2B7—NRF2 pathway—NRG1—thyroid cancer	0.000157	0.00765	CbGpPWpGaD
Silodosin—ADRA1A—GPCR ligand binding—CALCB—thyroid cancer	0.00015	0.00729	CbGpPWpGaD
Silodosin—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000141	0.00684	CbGpPWpGaD
Silodosin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000138	0.00668	CbGpPWpGaD
Silodosin—ABCB4—Metabolism—TPR—thyroid cancer	0.000126	0.00611	CbGpPWpGaD
Silodosin—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000124	0.00603	CbGpPWpGaD
Silodosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000124	0.00601	CbGpPWpGaD
Silodosin—ABCB4—Metabolism—PRKAR1A—thyroid cancer	0.000124	0.00601	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—MINPP1—thyroid cancer	0.000117	0.0057	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—CALCB—thyroid cancer	0.000115	0.00559	CbGpPWpGaD
Silodosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.000113	0.0055	CbGpPWpGaD
Silodosin—ABCB4—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000112	0.00545	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—CALCB—thyroid cancer	0.000105	0.00507	CbGpPWpGaD
Silodosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000103	0.00499	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—NDUFA13—thyroid cancer	9.98e-05	0.00484	CbGpPWpGaD
Silodosin—ABCB1—HIF-1-alpha transcription factor network—TERT—thyroid cancer	9.95e-05	0.00483	CbGpPWpGaD
Silodosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	9.63e-05	0.00467	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—CALCB—thyroid cancer	9.55e-05	0.00464	CbGpPWpGaD
Silodosin—ABCB1—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	9.51e-05	0.00462	CbGpPWpGaD
Silodosin—ADRA1D—GPCR ligand binding—TSHR—thyroid cancer	9.43e-05	0.00458	CbGpPWpGaD
Silodosin—ABCB4—Metabolism—SLC5A5—thyroid cancer	9.42e-05	0.00457	CbGpPWpGaD
Silodosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	9.4e-05	0.00457	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—CHST14—thyroid cancer	9.38e-05	0.00456	CbGpPWpGaD
Silodosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	9.13e-05	0.00443	CbGpPWpGaD
Silodosin—ABCB4—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	8.83e-05	0.00429	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—CALCB—thyroid cancer	8.67e-05	0.00421	CbGpPWpGaD
Silodosin—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	8.52e-05	0.00414	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—CALCB—thyroid cancer	8.48e-05	0.00412	CbGpPWpGaD
Silodosin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	8.47e-05	0.00411	CbGpPWpGaD
Silodosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	8.35e-05	0.00406	CbGpPWpGaD
Silodosin—ADRA1D—GPCR ligand binding—PTCH1—thyroid cancer	8.02e-05	0.00389	CbGpPWpGaD
Silodosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	7.99e-05	0.00388	CbGpPWpGaD
Silodosin—ABCB4—Metabolism—RXRA—thyroid cancer	7.91e-05	0.00384	CbGpPWpGaD
Silodosin—ADRA1B—GPCR ligand binding—TSHR—thyroid cancer	7.83e-05	0.0038	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—CALCB—thyroid cancer	7.7e-05	0.00374	CbGpPWpGaD
Silodosin—ABCB4—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	7.7e-05	0.00374	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—HPGD—thyroid cancer	7.56e-05	0.00367	CbGpPWpGaD
Silodosin—ADRA1D—GPCR ligand binding—SST—thyroid cancer	7.33e-05	0.00356	CbGpPWpGaD
Silodosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	7.1e-05	0.00345	CbGpPWpGaD
Silodosin—ADRA1D—GPCR ligand binding—CALCA—thyroid cancer	7.06e-05	0.00343	CbGpPWpGaD
Silodosin—ADRA1A—GPCR ligand binding—TSHR—thyroid cancer	6.95e-05	0.00337	CbGpPWpGaD
Silodosin—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	6.91e-05	0.00335	CbGpPWpGaD
Silodosin—ADRA1B—GPCR ligand binding—PTCH1—thyroid cancer	6.65e-05	0.00323	CbGpPWpGaD
Silodosin—ADRA1B—LPA receptor mediated events—HRAS—thyroid cancer	6.51e-05	0.00316	CbGpPWpGaD
Silodosin—ADRA1B—AMPK Signaling—TP53—thyroid cancer	6.41e-05	0.00311	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CALCB—thyroid cancer	6.17e-05	0.003	CbGpPWpGaD
Silodosin—ADRA1B—GPCR ligand binding—SST—thyroid cancer	6.09e-05	0.00295	CbGpPWpGaD
Silodosin—ADRA1A—GPCR ligand binding—PTCH1—thyroid cancer	5.91e-05	0.00287	CbGpPWpGaD
Silodosin—ADRA1B—GPCR ligand binding—CALCA—thyroid cancer	5.86e-05	0.00284	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—TRIM33—thyroid cancer	5.85e-05	0.00284	CbGpPWpGaD
Silodosin—ADRA1B—LPA receptor mediated events—AKT1—thyroid cancer	5.74e-05	0.00279	CbGpPWpGaD
Silodosin—ADRA1A—AMPK Signaling—TP53—thyroid cancer	5.69e-05	0.00276	CbGpPWpGaD
Silodosin—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	5.48e-05	0.00266	CbGpPWpGaD
Silodosin—ADRA1B—AMPK Signaling—AKT1—thyroid cancer	5.41e-05	0.00263	CbGpPWpGaD
Silodosin—ADRA1A—GPCR ligand binding—SST—thyroid cancer	5.41e-05	0.00262	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—TSHR—thyroid cancer	5.33e-05	0.00259	CbGpPWpGaD
Silodosin—ADRA1A—GPCR ligand binding—CALCA—thyroid cancer	5.2e-05	0.00253	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CALCB—thyroid cancer	5.12e-05	0.00249	CbGpPWpGaD
Silodosin—ABCB4—Metabolism—PPARG—thyroid cancer	5e-05	0.00243	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—TRIM33—thyroid cancer	4.86e-05	0.00236	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—TSHR—thyroid cancer	4.84e-05	0.00235	CbGpPWpGaD
Silodosin—ADRA1A—AMPK Signaling—AKT1—thyroid cancer	4.8e-05	0.00233	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—PRKAR1A—thyroid cancer	4.76e-05	0.00231	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CALCB—thyroid cancer	4.55e-05	0.00221	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—TSHR—thyroid cancer	4.42e-05	0.00215	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—MINPP1—thyroid cancer	4.37e-05	0.00212	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—TPR—thyroid cancer	4.34e-05	0.00211	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—TRIM33—thyroid cancer	4.31e-05	0.00209	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—PRKAR1A—thyroid cancer	4.27e-05	0.00207	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—SST—thyroid cancer	4.14e-05	0.00201	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—PTCH1—thyroid cancer	4.11e-05	0.002	CbGpPWpGaD
Silodosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	4.06e-05	0.00197	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—TSHR—thyroid cancer	4.02e-05	0.00195	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—CALCA—thyroid cancer	3.99e-05	0.00194	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—PRKAR1A—thyroid cancer	3.95e-05	0.00192	CbGpPWpGaD
Silodosin—ABCB4—Metabolism—PTGS2—thyroid cancer	3.93e-05	0.00191	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—TSHR—thyroid cancer	3.93e-05	0.00191	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—TCF7L1—thyroid cancer	3.9e-05	0.0019	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—SST—thyroid cancer	3.76e-05	0.00183	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—NDUFA13—thyroid cancer	3.72e-05	0.00181	CbGpPWpGaD
Silodosin—CYP3A4—Biological oxidations—RXRA—thyroid cancer	3.67e-05	0.00178	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—CALCA—thyroid cancer	3.62e-05	0.00176	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—TSHR—thyroid cancer	3.57e-05	0.00173	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—PRKAR1A—thyroid cancer	3.51e-05	0.0017	CbGpPWpGaD
Silodosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	3.5e-05	0.0017	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—CHST14—thyroid cancer	3.5e-05	0.0017	CbGpPWpGaD
Silodosin—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	3.46e-05	0.00168	CbGpPWpGaD
Silodosin—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	3.46e-05	0.00168	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—SST—thyroid cancer	3.44e-05	0.00167	CbGpPWpGaD
Silodosin—ABCB4—Metabolism—PTEN—thyroid cancer	3.43e-05	0.00166	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—PTCH1—thyroid cancer	3.41e-05	0.00166	CbGpPWpGaD
Silodosin—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	3.4e-05	0.00165	CbGpPWpGaD
Silodosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	3.37e-05	0.00164	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—CALCA—thyroid cancer	3.31e-05	0.00161	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—CDK1—thyroid cancer	3.28e-05	0.00159	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—SLC5A5—thyroid cancer	3.25e-05	0.00158	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—TCF7L1—thyroid cancer	3.24e-05	0.00157	CbGpPWpGaD
Silodosin—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	3.2e-05	0.00155	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—SST—thyroid cancer	3.12e-05	0.00152	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—SST—thyroid cancer	3.05e-05	0.00148	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—PTCH1—thyroid cancer	3.03e-05	0.00147	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—CALCA—thyroid cancer	3.01e-05	0.00146	CbGpPWpGaD
Silodosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	3e-05	0.00145	CbGpPWpGaD
Silodosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	2.97e-05	0.00144	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—CALCA—thyroid cancer	2.94e-05	0.00143	CbGpPWpGaD
Silodosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	2.9e-05	0.00141	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—TCF7L1—thyroid cancer	2.88e-05	0.0014	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—TSHR—thyroid cancer	2.86e-05	0.00139	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—HPGD—thyroid cancer	2.82e-05	0.00137	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PRKAR1A—thyroid cancer	2.81e-05	0.00137	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—SST—thyroid cancer	2.77e-05	0.00135	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—RXRA—thyroid cancer	2.73e-05	0.00133	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—CDK1—thyroid cancer	2.72e-05	0.00132	CbGpPWpGaD
Silodosin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	2.72e-05	0.00132	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—MINPP1—thyroid cancer	2.7e-05	0.00131	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MEN1—thyroid cancer	2.69e-05	0.0013	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—CALCA—thyroid cancer	2.67e-05	0.0013	CbGpPWpGaD
Silodosin—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	2.59e-05	0.00126	CbGpPWpGaD
Silodosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	2.58e-05	0.00125	CbGpPWpGaD
Silodosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	2.47e-05	0.0012	CbGpPWpGaD
Silodosin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	2.46e-05	0.00119	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PTCH1—thyroid cancer	2.43e-05	0.00118	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—CDK1—thyroid cancer	2.42e-05	0.00117	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—TSHR—thyroid cancer	2.37e-05	0.00115	CbGpPWpGaD
Silodosin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	2.37e-05	0.00115	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PRKAR1A—thyroid cancer	2.33e-05	0.00113	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—NDUFA13—thyroid cancer	2.29e-05	0.00111	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MEN1—thyroid cancer	2.23e-05	0.00108	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—SST—thyroid cancer	2.22e-05	0.00108	CbGpPWpGaD
Silodosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	2.19e-05	0.00106	CbGpPWpGaD
Silodosin—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	2.17e-05	0.00106	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CHST14—thyroid cancer	2.15e-05	0.00105	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CALCA—thyroid cancer	2.14e-05	0.00104	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—TSHR—thyroid cancer	2.11e-05	0.00102	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PRKAR1A—thyroid cancer	2.07e-05	0.00101	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PTCH1—thyroid cancer	2.02e-05	0.000979	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MEN1—thyroid cancer	1.98e-05	0.000962	CbGpPWpGaD
Silodosin—ABCB4—Metabolism—AKT1—thyroid cancer	1.98e-05	0.000959	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CDK1—thyroid cancer	1.94e-05	0.00094	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—SST—thyroid cancer	1.84e-05	0.000896	CbGpPWpGaD
Silodosin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	1.82e-05	0.000884	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PTCH1—thyroid cancer	1.79e-05	0.00087	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CALCA—thyroid cancer	1.78e-05	0.000862	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—HPGD—thyroid cancer	1.74e-05	0.000843	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—PPARG—thyroid cancer	1.72e-05	0.000837	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—SST—thyroid cancer	1.64e-05	0.000796	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—TPR—thyroid cancer	1.62e-05	0.000786	CbGpPWpGaD
Silodosin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	1.62e-05	0.000786	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CDK1—thyroid cancer	1.61e-05	0.00078	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PRKAR1A—thyroid cancer	1.59e-05	0.000773	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CALCA—thyroid cancer	1.58e-05	0.000766	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—NRG1—thyroid cancer	1.55e-05	0.000755	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CDK1—thyroid cancer	1.43e-05	0.000693	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—TERT—thyroid cancer	1.4e-05	0.000678	CbGpPWpGaD
Silodosin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.37e-05	0.000664	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—PTGS2—thyroid cancer	1.36e-05	0.000659	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—HIF1A—thyroid cancer	1.33e-05	0.000648	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—NRG1—thyroid cancer	1.29e-05	0.000626	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.21e-05	0.000588	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—PTEN—thyroid cancer	1.18e-05	0.000575	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—NRAS—thyroid cancer	1.18e-05	0.000571	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—TERT—thyroid cancer	1.16e-05	0.000563	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—NRG1—thyroid cancer	1.15e-05	0.000556	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—HIF1A—thyroid cancer	1.11e-05	0.000538	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—BRAF—thyroid cancer	1.11e-05	0.000537	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—TERT—thyroid cancer	1.03e-05	0.0005	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—RXRA—thyroid cancer	1.02e-05	0.000494	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—KRAS—thyroid cancer	1.01e-05	0.000491	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—TPR—thyroid cancer	9.98e-06	0.000484	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—HIF1A—thyroid cancer	9.84e-06	0.000478	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	9.81e-06	0.000476	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—NRAS—thyroid cancer	9.76e-06	0.000474	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—BRAF—thyroid cancer	9.17e-06	0.000445	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—NRAS—thyroid cancer	8.67e-06	0.000421	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—HRAS—thyroid cancer	8.6e-06	0.000418	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—KRAS—thyroid cancer	8.4e-06	0.000408	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—AKT1—thyroid cancer	8.37e-06	0.000406	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—BRAF—thyroid cancer	8.15e-06	0.000396	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CCND1—thyroid cancer	8.07e-06	0.000392	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PTEN—thyroid cancer	7.79e-06	0.000378	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—AKT1—thyroid cancer	7.6e-06	0.000369	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—SLC5A5—thyroid cancer	7.47e-06	0.000363	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—KRAS—thyroid cancer	7.46e-06	0.000362	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—HRAS—thyroid cancer	7.14e-06	0.000347	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—NRAS—thyroid cancer	6.95e-06	0.000337	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—AKT1—thyroid cancer	6.94e-06	0.000337	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—AKT1—thyroid cancer	6.82e-06	0.000331	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CCND1—thyroid cancer	6.7e-06	0.000325	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PTEN—thyroid cancer	6.46e-06	0.000314	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PPARG—thyroid cancer	6.43e-06	0.000312	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—HRAS—thyroid cancer	6.34e-06	0.000308	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—AKT1—thyroid cancer	6.3e-06	0.000306	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—RXRA—thyroid cancer	6.27e-06	0.000305	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—AKT1—thyroid cancer	6.17e-06	0.000299	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—KRAS—thyroid cancer	5.98e-06	0.00029	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CCND1—thyroid cancer	5.95e-06	0.000289	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—NRAS—thyroid cancer	5.77e-06	0.00028	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PTEN—thyroid cancer	5.74e-06	0.000279	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—AKT1—thyroid cancer	5.6e-06	0.000272	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—TP53—thyroid cancer	5.31e-06	0.000258	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—NRAS—thyroid cancer	5.12e-06	0.000249	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—HRAS—thyroid cancer	5.08e-06	0.000247	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PTGS2—thyroid cancer	5.06e-06	0.000246	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—KRAS—thyroid cancer	4.96e-06	0.000241	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—AKT1—thyroid cancer	4.49e-06	0.000218	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PTEN—thyroid cancer	4.41e-06	0.000214	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—TP53—thyroid cancer	4.41e-06	0.000214	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—KRAS—thyroid cancer	4.41e-06	0.000214	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—HRAS—thyroid cancer	4.22e-06	0.000205	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PPARG—thyroid cancer	3.96e-06	0.000192	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—TP53—thyroid cancer	3.92e-06	0.00019	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—HRAS—thyroid cancer	3.75e-06	0.000182	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—AKT1—thyroid cancer	3.72e-06	0.000181	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—AKT1—thyroid cancer	3.31e-06	0.000161	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PTGS2—thyroid cancer	3.12e-06	0.000151	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PTEN—thyroid cancer	2.72e-06	0.000132	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—AKT1—thyroid cancer	2.54e-06	0.000123	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—AKT1—thyroid cancer	1.57e-06	7.6e-05	CbGpPWpGaD
